Most people with long-duration type 1 diabetes in a large population-based study are insulin microsecretors

Diabetes Care

Volumn 38, Issue 2, 2015, Pages 323-328

  Oram, Richard A ^a   McDonald, Timothy J ^a,b   Shields, Beverley M ^a   Hudson, Michelle M ^a   Shepherd, Maggie H ^a   Hammersley, Suzanne ^a   Pearson, Ewan R ^c   Hattersley, Andrew T ^a   Sanders, Tina ^d   Tiley, Sarah ^d   Gellatly, Emma ^e   Beall, Lynsey ^e   Shepherd, Bridget ^e   Colhune, Helen ^f   Colclough, Kev ^f   Ellard, Sian ^f  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d Exeter Medical School   (United Kingdom)

^e Dundee College   (United Kingdom)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CREATININE; INSULIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POPULATION RESEARCH; PREDICTOR VARIABLE; PROTEIN URINE LEVEL; UNITED KINGDOM; URINALYSIS; BLOOD; CLINICAL TRIAL; METABOLISM; MULTICENTER STUDY; PHYSIOLOGY; POSTPRANDIAL STATE; SECRETION (PROCESS); TIME; URINE; YOUNG ADULT;

ADULT; C-PEPTIDE; CHILD; CREATININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIA; INSULIN; MALE; POSTPRANDIAL PERIOD; TIME FACTORS; YOUNG ADULT;

EID: 84921914093     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-0871     Document Type: Article

References (21)

1. Oram RA, Jones AG, Besser RE, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia 2014;57:187-191
2. Wang L, Lovejoy NF, Faustman DL. Persistence of prolonged C-peptide production in type 1 diabetes as measured with an ultrasensitive C-peptide assay. Diabetes Care 2012;35:465-470
3. Keenan HA, Sun JK, Levine J, et al. Residual insulin production and pancreatic b-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 2010;59:2846-2853
4. McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 2009;55:2035-2039
5. Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT. Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes. DiabetMed 2012;29:90-93
6. Besser RE, Ludvigsson J, Jones AG, et al. Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011;34:607-609
7. Jones AG, Besser RE, McDonald TJ, et al. Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med 2011;28:1034-1038
8. Besser RE, Shepherd MH, McDonald TJ, et al. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-alpha/hepatocyte nuclear factor 4-alpha maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011;34:286-291
9. Ellard S, Lango Allen H, De Franco E, et al. Improved genetic testing for monogenic diabetes using targeted next-generation sequencing. Diabetologia 2013;56:1958-1963
10. Besser RE, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT. The impact of insulin administration during the mixed meal tolerance test. Diabet Med 2012;29:1279-1284
11. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003;26:832-836
12. Lachin JM, McGee P, Palmer JP; DCCT/EDIC Research Group. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014;63:739-748
13. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998;128:517-523
14. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 2013;30:803-817
15. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17-24
16. Meier JJ, Bhushan A, Butler AE, Rizza RA, Butler PC. Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? Diabetologia 2005;48:2221-2228
17. Dabelea D, Mayer-Davis EJ, Andrews JS, et al. Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study. Diabetologia 2012;55:3359-3368
18. Besser RE, Shields BM, Casas R, Hattersley AT, Ludvigsson J. Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 2013;36:195-201
19. Barker A, Lauria A, Schloot N, et al. Agedependent decline of b-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab 2014;16:262-267
20. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve b-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53:250-264
21. Oram RA, Rawlingson A, Shields BM, et al. Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ Open 2013;3:e003193